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ABSTRACT 
Cardiac myxomas are rare benign and slowly proliferating neoplasms of uncertain 
histogenesis with heterogeneous histomorphology and variable and sometimes clinically quite 
malignant pathological manifestations. Majority of cardiac myxoma occur sporadically while 
a relatively small proportion of diagnosed cases develop as a part of Carney complex 
syndrome with established familial pattern of inheritance. Although histologically 
indistinguishable these two forms of cardiac myxoma exhibit distinct cytogenetic make-up 
and apparent pathological differences important for their clinical presentation and prognosis. 
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Additional problem is presented with secondary lesions with more aggressive histology and 
significantly faster cell proliferation suggesting their successive malignant alteration. Surgical 
resection of cardiac myxoma is currently the only treatment of choice. However, to avoid 
potentially hazardous operating procedures and possible postoperative complications and to 
prevent recurrence of the neoplastic lesions it is necessary to develop alternative approaches 
and identify a possible drug targets for their successful pharmacological treatment. Due to the 
rarity of the disease, a small number of cases in one institution and lack of comprehensive 
experimental data particularly concerning the cases of metastatic dissemination and secondary 
lesions with malignant nature, a comprehensive multi-institutional approach is required for 
better understanding of their molecular pathology and illumination of key molecular, genetic 
as well as epigenetic markers and regulatory pathways responsible for their development. In 
this article we provide comprehensive pathohistological, molecular and cytogenetic overview 
of sporadic cardiac myxoma cases restating the major hypothesis concerning their 
histogenesis and emphasizing potential approaches for their further reexamination. 
 
INTRODUCTION 
Cardiac myxoma (CM) represents the most prevalent type of primary cardiac tumors in 
adults, constituting up to 50-85% of all benign lesions [1, 2, 3 and 4]. Contrary, during fetal 
development, infancy and childhood, CM makes only 15% of cardiac tumors with most of 
them found in older children [5, 6, and 7]. 
CMs are benign, slowly proliferating neoplasms that do not infiltrate into the myocardium 
and usually do not form metastatic lesions [1, 2, 3 and 4].  
Due to their strategic localization and inherent pathohistological characteristics, they are 
clinically considered as quite malignant entities with very serious consequences for morbidity 
and mortality of affected patients [1 and 8]. 
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Estimated incidence of CM is approximately 0.5-1 cases per 10
6
 individuals per year, with 
apparent preponderance (3:1) of female patients [9 and 10]. 
Although usually diagnosed between the fourth and sixth decade of life, CM may be 
encountered in any age group, though rarely among children and with extremely rare 
occurrence during foetal and neonatal periods of life [6, 7 and 11].  
The nomenclature of CMs is based on the cardiac chamber in which they arise (atrial vs. 
ventricular), the side of the heart affected (left vs. right-sided) and the exact position of their 
attachment within the given cardiac chamber (posterior or anterior wall, interatrial septum or 
atrial appendage). Their name derives from the prevalent myxoid extracellular matrix rich in 
glycoproteins and proteoglycans [2]. 
The majority of CMs (60-80%) are diagnosed within the left atrium, arising mainly from the 
interatrial septum of the fosae ovalis border [2, 3 and 6]. They may also originate from 
anywhere within the atrium including the posterior and anterior endocardial tissue and 
appendage [12].  
About 15-28% cases of CM are diagnosed in the right atrium, 8% in the right, and 3-4% in 
the left ventricle. Ventricular cases of CM are mainly found in women and children. A small 
proportion of CMs (1.6-8.5%) are biatrial, and approximately 1.6% has multifocal origin [2, 
3, 5 and 12].
 
 
There are also rare reports of CM originating from anterior and posterior mitral leaflets, 
pulmonary artery and vein, aortic valves, inferior vena cava and superior part of interatrial 
septum [12, 13, 14, 15 and 16].  
Majority of CM (90%) occur sporadically, while only 5-10% have established familial pattern 
of inheritance [17, 18, 19 and 20].  
Hereditary form of CM occurs as a part of Carney complex (CNC) syndrome, characterized 
with variable phenotypic expression but nearly complete penetrance.  
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CNC is an autosomal-dominant disease in which cardiac and extracardiac myxoma [skin, 
breast] arise in settings of spotty skin pigmentation [blue nevi, lentiginoze, ephelides, cafe-au-
lait spots], endocrine tumors and overactivity (pituitary adenoma with acromegaly or 
gigantism, primary pigmented nodular adrenocortical disease [PPNAD], thyroid tumors] and 
other neoplastic lesions [testicular large-cell calcifying Sertoli-cell tumors [LCCSCT], 
psammomatous melanotic schwanoma [PMS])
 
[21].  
Although sporadic and hereditary types of CM are histologically quite indistinguishable there 
are some subtle but clinically still apparent differences in their presentation and prognosis.  
Sporadic cases frequently arise as isolated and solitary left atrial tumors in middle age female 
patients, whereas familial myxoma can occur in any cardiac chambers (quite often as 
multicentric neoplasia), usually at an earlier period of life and with no apparent gender 
preferences. Furthermore, patients with CNC more often develop recurrent tumors despite 
adequate surgical resection of the initial lesion [22].  
 
Clinical presentation  
CM may stimulate enormously wide spectrum of potentially misleading cardiac and 
noncardiac symptoms and signs, therefore completely deserving the infamy of the "great 
imitators" in clinical medicine [2].  
Clinical presentation depends primarily on their location (left or right cardiac chamber), size 
and mobility and to a lesser degree on their overall morphology [10, 23, 24, 25 and 26].  
Some patients (10-15%) show no clinically visible signs, particularly in the case of small 
neoplasms (˂ 40 mm) and the tumor is diagnosed entirely by chance during routine 
examinations for other pathological conditions or at autopsy [1 and 8].  
Contrary, in some clinically advanced patients, due to the strategic location, large size and 
inherent fragmentation CM may precipitate acute heart failure and sudden death [27].  
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Patients with CM generally present with one or more symptoms of classical triad of: 
hemodynamic derangement due to the intracardiac obstruction, signs of systemic (peripheral 
or cerebral) or pulmonary embolisation and/or nonspecific constitutional symptoms [1, 2, 3 
and 8]. 
Intracardiac obstruction with congestive heart failure is the prevailing cause of acute 
presenting symptoms of CM that provokes their initial diagnosis, while the neurological and 
other symptoms of systemic and pulmonary embolism are slightly less common. 
 
Intracardiac obstruction  
Intracardiac obstruction is initially observed in 50% of patients but may reveal itself later, at 
any time during the disease progression, encompassing finally up to 70% of all affected 
patients [26 and 28].  
Hemodynamic derangements commonly give rise to symptoms of left (dyspnea, paroxysmal 
nocturnal dyspnea, orthopnea, pulmonary and peripheral edema, pulmonary hypertension) or 
right-sided (peripheral edema, ascites, hepatomegaly, other symptoms of venous 
hypertension) heart failure [2, 28, 29, 30, 31 and 32]. 
The severity of symptoms is characteristically progressive and depends primarily on 
obstruction intensity (tumor size), and in some cases, postural changes of afflicted patients.  
The predominant abnormality is the obstruction of heart valve orifices often mimicking 
clinical signs of mitral or tricuspid valve stenosis. 
Obstruction occurs more commonly with large pedunculated tumors with soft, easily 
deformable tissue. Occasionally, CM may even cause complete temporary occlusion of 
corresponding valve orifice, resulting in dizziness, intermittent positional syncope, or sudden 
death [2, 3 and 27].  
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In some patients frequent back-and-forth motions of deformable tumor tissue between 
originating and adjacent cardiac chamber ("wrecking ball" effect) may interfere with proper 
closure of valve orifice causing mitral or tricuspid valve regurgitation and/or damage to their 
supporting structures (chordae tendine) with concomitant development of signs of mitral or 
tricuspid valve insufficiency [33].  
Mitral valve stenosis represents the most common problem of differential diagnosis 
associated with the left atrial myxoma [2].  
Occasionally, CM and mitral valve stenosis may occur as separate clinical entities 
concomitantly present in the same patient, which further complicates the emerging clinical 
picture and postpones timely and comprehensive diagnosis of existing disease/s [34 and 35].  
Right atrial myxomas often mimic the symptoms of tricuspid valve stenosis or insufficiency 
but they may also disclose clinical signs of constrictive pericarditis and pulmonary 
hypertension [29, 36 and 37].  
Ventricular myxomas are more often sessile and less frequently responsible for intracardiac 
obstruction [2 and 3]. In the cases when they are sufficiently large and/or strategically located 
in subaortic or subpulmonary regions they may cause obstruction of blood outflow mimicking 
the symptoms of pulmonary or aortic valve stenosis [38, 39, 40 and 41].  
Obstruction of blood flow may also be caused by rare cases of CM arising directly in the 
valve tissue, therefore leading to symptoms of stenosis, regurgitation and other signs of 
valvular insufficiency. 
 
Embolism  
Embolic manifestations have been observed in 30-50% of CM patients. They are caused by 
tissue fragmentation, detachment of tumor as a whole and/or dissemination of overlaying 
thrombi or foci of existing vegetation from tumor surface.  
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Due to the prevailing left-sided location of CM, systemic embolisms (cerebral and peripheral) 
are most frequently encountered. Primarily in cerebral and retinal arteries followed by arteries 
of the lower extremities, visceral, renal and coronary arteries, and sometimes even in the 
abdominal aorta [42, 43, and 44].  
More than 50% of embolic events caused by CM affect the central nervous system (CNS) and 
retinal arteries, resulting in intracranial and extracranial vascular obstructions, eyesight 
disorders, cerebral infarction, seizure and brain necrosis or intracranial aneurysms, 
hemiparesis, aphasia, and progressive dementia [45, 46, 47, 48, 49 and 50].  
Due to quite common embolisation of CNS some authors suggest careful histopathological 
evaluations of all CNS emboli to differentially exclude CM as their possible cause.  
Lower extremities are the next anatomic sites frequently targeted by embolic material from 
left-sided myxoma [51, 52and 53].  
In these settings they are occasionally misdiagnosed as peripheral vasculitis (collagen 
vascular disease) with unknown etiology [54]. This further emphasizes the importance of 
histological evaluation of all embolectomy specimens [55].  
Although the embolisation of cardiac vasculature is rarely recorded, sometimes it may 
represent the very first clinical sign of CM resulting with occlusion and angina or fatal 
myocardial infarction [56, 57 and 58].  
Right-sided CM rarely provokes embolic events (10%). In those cases they may effectuate 
obstruction of pulmonary artery, resulting with pulmonary hypertension or even fatal 
fulminant pulmonary obstruction [2 and 42].  
 
Constitutional manifestation  
Constitutional manifestations are present in almost 90% of CM patients [1, 2 and 3]. They 
usually occur independently of tumor size and location and commonly include physical 
8 
 
weakness, lethargy, fatigue, loss of appetite, anorexia, recent and progressive decrease in 
body weight and persistent and unexplained low-grade fever. 
Myxoma may also effectuate development of arthralgia, myalgia, facial edema, hyperhidrosis 
and nocturnal haemopthysis (caused by edema and pulmonary embolization), deformed digits 
(clubbed/drumstick fingers), and non-specific cutaneous lesions (erythematous rash, 
petechiae, Raynauds phenomenon).  
They are accompanied by abnormal laboratory findings such as chronic anemia 
(normocromatic, hypercromatic, hemolytic), and elevated inflammatory markers (elevated 
white blood cells, polycythemia /erythrocytosis/ and elevated erythrocyte sedimentation rate, 
increased level of serum C-reactive proteins and elevated immunoglobulin levels.  
Less common are leukocytosis, thrombocytopenia (disturbances of clotting mechanism such 
as disseminated intravascular coagulation), cyanosis and presence of antinuclear and rarely 
antiphospholipid autoantibodies [1, 2, 3 and 25].  
Nonspecific constitutional an extracardiac symptoms, signs, and complications, may also 
present the initial manifestations contributing to clinical misinterpretation or delay in 
diagnosis of CM.  
Laboratory abnormalities may be misinterpreted as signs of infection (infective endocarditis, 
rheumatic heart disease), immunological disorders (e.g. rheumatoid arthritis, vasculitis, 
collagen vascular disease, and autoimmune disease) and occult malignant diseases [25, 54, 
59, 60 and 61].  
The etiologies of constitutional manifestation are not fully understood. They may emerge as 
nonspecific consequences of embolization (facial edema, myalgia, arthralgia, nocturnal 
haemopthysis), erythropoietin production by some atrial myxoma (erythrocytosis), 
mechanical destruction of cells by abnormal blood flow across the tumor surface 
(thrombocytopenia, hemolytic anemia- particularly associated with calcified tumors) or 
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autocrine production of cytokines such as IL6 and IL8 (inflammatory and autoimmune 
responses), accompanied by activation of complement cascade by circulating antibody-tumor-
antigen complexes [62, 63, 64 and 65].  
All constitutional manifestations are usually reversible and completely resolved after 
complete surgical excision of tumor tissue.  
 
Infection  
Although often present with constitutional symptoms mimicking infective endocarditis, CMs 
are rarely actually infected.  
In most of the cases isolated pathogens belonged to the Streptococcus species (Streptococcus 
viridans, Streptococcus oralis, and Streptococcus mutans). There are also reports of CM 
infected by other bacterial and fungal pathogens (Enterococcus faecalis, Staphylococcus 
lugdunensis, Gemella morbillorum, Porphyromonas asaccharolytica, Candida albicans and 
Histoplasma capsulatum) [65, 66, 67, 68, 69, 70, 71, 72 and 73].  
Superimposed infective processes render tumor tissue even more friable and prone to 
systemic embolization.  
 
Recurrence and malignant potential of cardiac myxoma 
Complete surgical resection of tumor tissue is currently the only treatment of choice for 
effective therapy of cardiac myxoma.  
The surgery should be performed as soon as possible due to prominent danger of embolism, 
obstruction and sudden death registered in approximately 8-10% of patients awaiting 
operation [74]. 
Recurrence after surgical resection of primary lesions has been observed in 1-4% of sporadic 
and 12-22% of familial (CNC) cases [2, 3 and 12].
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Secondary lesions usually occur as unifocal resurgence at or near the site of primary tumor or 
they can emerge in previously healthy endocardium of the original or other cardiac chambers 
[75 and 76]. Multiple secondary lesions are also recorded (even when the original tumor was 
single) as well as metastatic extracardiac lesions in arteries, bones, brain and other soft tissues 
[77, 78, 79, 80 and 81].  
Re-recurrence is unlikely and only a few cases have been recorded [82, 83 and 4]. 
Secondary lesions are more common in younger patients. They may occur within just a few 
months or up to several years after the initial resection (average 4 years). There is also a 
report of patient in whom secondary lesion was diagnosed 20 years after the removal of 
primary tumor [85].  
The explanation for the intracardiac recurrence can be found in familiar predisposition, 
unrecognized multicentric origin of primary lesion, incomplete resection or intraoperative 
dissemination of tumor cells and the de novo proliferation of the pretumor or reserve cells 
reportedly present in the endocardium [2, 4 and 86].  
Although repeatedly hypothesized since the first reported case of recurrent left-sided atrial 
myxoma in 1967, relationship
 
of local intracardial recurrence with the adequacy of the 
surgical resection
 
is quite controversial. It appears that recurrent tumors often do not resurge 
at the site of the original lesion even
 
in the cases when complete excision has not been done 
[8]. Furthermore, number of large series of postsurgical follow-up reported no recurrent 
tumors.  
Biological characteristics of the CM assessed through expression analysis of tumor tissues 
and detection of existing DNA mutations, rather than their overall pathohistological 
presentation, may be the most reliable factor for recurrence prediction. 
The recurrence is highest among patients with CNC and all of them carry some sort of DNA 
mutations [4 and 8].  
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Abnormal DNA has also been recorded in 20% of sporadic CM and their recurrence rate (12-
40%) was significantly higher compared to overall sporadic cases (1, 2, 3, 4 and 8). 
Additional problem is presented with sporadic CM recurring in distant regions of the body, 
especially the ones with apparently malignant nature [4, 87, 88, 89 and 90].  
As a plausible explanation for their metastatic recurrence in local and distant extracardiac 
regions some authors propose survival of neoplastic cells in disseminated tissue fragments or 
detached overlaying thrombi and their further growth at the site of embolization. Other 
authors, taking into account the benign histology of primary lesion, consider that mechanism 
as quite unconvincing [4].  
There are also reports of recurrent lesions with more aggressive histology and significantly 
faster cell proliferation, suggesting successive malignant alteration of benign tumors in their 
new settings [4, 87, 88, 89 and 90]. 
A more likely explanation may be that sporadic CM that later metastasize was a mistaken 
identity of the malignant primary tumor like myxsosarcoma, fibromyxosarcoma, 
chondrosarcoma or malignant fibrous histocitoma [91, 92, 93 and 94].  
Only a few molecular studies have been conducted to evaluate proliferative activity and 
metastatic potential of CM or to establish expression pattern and polymorphism of proto-
oncogenes and tumor suppressor genes in their cells. According to them CM represent a 
weekly proliferative lesion with little metastatic potential. All proto-oncogenes and tumor 
suppressors gene studied in those experiments showed either no (e.g. p53) or minor 
expressional modulation and/or genetic abnormalities of investigated proto-oncogene and 
tumor suppressor genes (Rb1, Bcl-2,) [95 and 96].  
Expression microarray analysis reported in 2004 showed more than 10-fold higher expression 
of melanoma inhibitory activity (MIA) in sporadic CMs compared to normal tissues controls 
[97].  
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MIA has an important role in malignant transformation, growth, invasion, dissemination, drug 
resistance and immunoreactivity of malignant melanomas.  
MIA was also reported in ovarian, renal and head/neck carcinomas as well as in many 
patients with breast and advanced gastrointestinal carcinomas. It seems that in number of 
patients increased MIA expression also correlates with progression to systemic metastasis and 
a poor prognosis [98]. 
Interestingly, an isoform of S100 protein, another molecular marker found in sporadic cardiac 
myxoma, has been recently established as a second potential prognostic marker for patients 
with malignant melanomas [97]. Altered expression of S100 family members is seen in many 
cancers including breast, lung, bladder and kidney as well as thyroid, gastric, prostate and oral 
cancers [99].  
However, establishment of possible role (if any) of MIA and S100 (immunohistological 
studies report positive S100 staining without precise determination of protein isoforms) in 
tumor growth, recurrence and exact nature of their extracardiac dissemination or malignant 
potential of sporadic CMs requires further studies. 
Another factor that may explain or at least contribute to the malignant potential of otherwise 
histologically benign CM and/or the remote metastatic growth of embolized material (through 
direct stimulation of cell growth and/or induction of angiogenesis) is autocrine expression of 
VEGF and PDGF and its receptors (VGER1/Flt-1, VGFR2/KDR/Flk-1 and PDGFR α/β) 
detected in the cytoplasm of tumor cells [100, 101, 102 and 103].  
Inflammatory cytokine (IL6, IL8) abundantly secreted by neoplastic tissue also have the 
potential to enhance CM vascularisation and migration and proliferation of their cells. 
Important angiogenic signals may also be provided through action of monocyte chemotactic 
protein-1 (MCP-1) and thymidine phosphorilase (TP) whose expression is also detected in 
neoplastic myxoma cells (104). 
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Due to the rarity (number of cases presented in the same institution) of cases with seemingly 
malignant nature and lack of experimental data, sequential malignant transformation of 
primary benign tumor cells and the existence of malignant subpopulations of CMs is still a 
matter of high controversy.  
 
Macroscopy 
Cardiac myxomas have heterogeneous histomorphology that varies with their location, 
clinical presentation and age and gender of affected patient [1, 2, 3 and 12].  
They show variegated color, consistency and size with pale gray, white, yellow or brown, 
somewhat bosselated surface appearance and fibrous, gelatinous or myxoid structure admixed 
with superficial thrombi or hemorrhagic dark brown or red areas [1, 2, and 3].  
Their size range, from just a few millimeters up to 15 cm in diameter (average 5-6 cm), with 
corresponding weight from two to more than 250g [1, 2, 3 and 12].  
Majority of CM are polypoid, pedunculated (rarely sessile), round or ovoid tumors with 
smooth, glistening or slightly lobulated surface, and a short broad base [1, 2, 3 and 12]. 
Polypoid myxomas are usually compact, solid tumors with little tendency to spontaneous 
fragmentation.  
The less common are papillary myxoma with a multiple thinner or thicker villous, finger-like 
extensions and soft, gelatinous structure very prone to fragmentation, erosion and 
embolisation. [1, 2, 3 and 12]. 
As another source of embolisation papillary myxomas often contain superficial blood clots 
and hemorrhagic foci embedded among their villous extension. Contrary, in polypoid tumors 
hemorrhagic foci are more frequently internalize [105].  
It seems that the occurrence of these two types of CM is not merely a matter of random events 
during their development.  
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Papillary myxomas show significantly higher expression and activity of specific matrix-
metalloproteinases (MMP-MT1, MMP-2 and MMP-9), enzymes involved in extracellular 
matrix (ECM) remodeling [106].  
Their increased activity leads to amplified degradation of ECM, distorts the balance between 
synthetic and degradation processes that changes mechanical properties of tumor tissue and 
most probably facilitates its fragmentation, erosion and embolization by hemodynamic forces.  
Furthermore, initial findings suggest that increased expression of MUC5AC gene within 
tumor tissue of sporadic myxoma may correlate with lower risk of embolization [107 and 
108].  
The two morphological subtypes of CM may also be differentiated by their usual clinical 
presentation [109].  
Obstructive heart failure is usually associated with solid, polypoid tumors while neurologic 
and other embolic events represent the most common clinical feature of fragile papillary 
myxoma. Les frequently, turbulent blood flow can also lead to dissemination of emboli from 
the surface of solid myxoma [55 and 105].  
 
Histopathology 
CM are mainly composed of stellate, fusiform or elongated, polygonal (lepidic) cell 
incorporated into amorphous myxoid matrix [1, 2, 6, 12 and 110]. The cells usually occur 
solitary or arrange in small parallel clusters, short syncityal cords and vasiforme rings 
(multilayered circular structures around thin-wall blood vessels /perivascular cuffing/) and 
tubular structures [1, 2, 3, 105, 111, and 112].  
Neoplastic tumor cells contain oval, round or elongated nuclei with finely dispersed or 
vesicular chromatin structure, a small amount of highly eosinophilic cytoplasm and indistinct 
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cell membrane. Syncityal multinuclear (3-9 nuclei) giant tumour cells can also be seen. 
Mitoses are rarely observed [1, 2, 6, 12 and 110].  
Other cellular elements include variable number of blood cells (lymphocyte, erythrocyte, 
macrophage, mast cell, dendritic cell, plasma cell), histiocytes, fibroblasts and smooth muscle 
cells [1, 2 and 3].  
Atypical cellular and extracellular structures like well-defined columnar epithelium 
occasionally forming glandular structure (~2% of tumors; may be confused for metastatic 
adenocarcinomas), foci of extramedullary hematopoesis (~7%), chondrocytes and osteoblasts, 
calcification (~ 10%; more frequent in right atrial myxoma) and even metaplastic bone 
formation as well as cysts and degenerated collagen fibers encrusted with iron and calcium 
(Gamna-Gandy bodies) may also be encountered. Thymic rests have also been observed [113, 
114, and 115].  
The number of cells is highly variable, not only among tumors from different patients but also 
in different regions of the same specimen. The same heterogeneity applies for extracellular 
matrix and tumor vasculature. 
The surrounding weakly basophilic, afibrillar myxoid matrix is abundant in proteoglycans 
made of variable protein core covalently linked to one or multiple glycosaminoglycan (GAG) 
chains. More than 90% of GAGs are composed of chondroitin-6-sulfate, hyaluronic acid and 
chondroitin-4-sulfate [1, 2 and 116].  
Matrix contains variable amounts of elastin, fibrinogen, fibrin and collagen fibers and 
hemosiderin deposits scattered within the stroma or within histiocytes and myxoma cells [1, 2 
and 3].  
While only a subset of CM has macroscopically visible areas of hemorrhage, dispersed 
microscopic foci of recent and organizing hemorrhage is almost universal feature of all 
surgically resected tumors, also found in more than a half of the specimens obtained at 
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autopsy.
41
 Hemosiderin deposits and Gamna-Gandy bodies are also microscopic remnants of 
old episodes of hemorrhage [1 and 2].  
Myxomas are mostly perfused with thin walled blood vessels without pericytes while vessels 
with thicker muscle walls predominate at the base and in their stalk [1 and 2]. 
Tumor surface is covered with a single layer of flattened endothelial cells (multilayering may 
also be present) that form small vascular spaces or invaginations into the tumor stroma. Single 
layer of lepidic tumor cells may cover some surface regions [1, 2 and 3]. 
Superficial regions of CM tissue show a prominent collagenisation. That feature is absent in 
papillary tumor types. 
 
Histogenesis  
Controversy about the exact nature and histogenesis of CM exists since they were first 
described.  
Initially it was believed that they originate from organized intracardial thrombi [1, 2, 117 and 
118].  
Based on their prevailing location, histological organization, observed chromosomal 
abnormalities and DNA ploidy pattern it was soon recognized that they represent a distinct 
clinical entity [1, 2, 119 and 120].  
As the cardiac surgery and removal of neoplasms was gradually becoming a quite common 
procedure it was even more important to establish the criteria for their differentiation from 
other cardiac neoplasms, and to understand their histogenesis.  
However, the infrequency of CM and heterogeneous results from various phenotypic 
characterization studies has limited the potential and there is still no clear conclusion about 
their exact origin.  
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The presence of heterologus histological presentation still suggests to some authors that CM 
may be the consequence of some reactive (traumatic) or hamartomatous processes [95 and 
121].  
 
Viral origin  
Li et all in 2003 reported the presence of viral antigens and genetic material of herpes simplex 
virus type 1 (HSV1) in 70% of surgically removed sporadic CM [122].  
Although their research was conducted on a relatively small number of cases (n=17), due to 
the prevalence of myxoma with viral DNA (8/17) and HSV1 antigens (12/17) they suggested 
that at least some CM may result from a chronic inflammatory lesion of endocardial tissue 
induced by viral infection[122].  
Their hypothesis was further based on similar constitutional manifestations and abnormal 
laboratory findings present both in patients with CM and those with infective diseases [122].  
Furthermore, multinucleated giant cells present in CM correspond to giant cells found in 
tissues infected with HSV1, and absence of mitosis and MIB1/Ki67 expression in these cells 
suggests their formation through fusion of mononuclear cells, mediated by HSV1 
glycoproteins rather than proliferation [123 and 124]. Also, cuffing of the thin-walled blood 
vessels and microscopic hemorrhage present within myxoma tissue as well as fibrin 
deposition in tumor matrix histologically resembles lesions of solid tissues infected by HSV1 
[1,2,3 and 110]. IL6 and VEGF expression found in cells infected by HV1 is also established 
in CM and HSV1 replication in neurons of satellite cells of cardiac ganglia and endocardium 
also correlates with hypothesized neuroendocrine origin of CM [61, 62, 63, 64, 65, 101, 102, 
103, 125, 126 and 127].  
However, recent immunohistological studies conducted on a series of 70 patients with cardiac 
myxoma showed no association between HSV1 and occurrence of CMs [128].  
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Based on numerous immunohistological, ultrastructural and in vitro studies, most authors now 
believe that CM represents true benign neoplasms developed from sub-endothelial 
vasoformative reserve cells or primitive stem cells (multipotential mesenchimal cells) 
residing in the fosae ovalis and surrounding endocardium [1, 2 and 3].  
It is assumed that these multipotential mesenchimal cells exist in the endocardium as 
remnants of septation processes of the embryonic heart.  
 
Prichard’s structures  
Exploring the potential presence of precursor cells in the fossa ovalis and surrounding 
endocardium, in 1951 Prichard detected microscopic intracavitary and subendothelial 
structures (lacunas of capillary size lined by plump endothelial cells) with predilection for 
interatrial septum. For a time these “Pritchard’s structures” were correlated with histogenesis 
of CM [129].  
In order to confirm the existence of Prichard's structures and to clarify their possible role in 
histogenesis of CM, Acebo et all, and later Val-Bernal et all conducted a prospective, 
immunohistological studies of a large number (n1=100, n2=101) of interatrial septa [130 and 
131].  
Although they found structures similar to ones described by Prichard there were positive only 
for known markers of mature endothelial cells (vimentin+, CD31+, CD34+, 
thrombomodulin+, ckit/CD117 -; VEGFR2 -; Ki67 -) and negative for markers of 
embryonic/fetal endothelium and other primitive mesenchymal cells in various stages of 
differentiation (alpha-smooth muscle actin αSMA, S100 protein, calretinin CALB2, and c-
kit/CD117).  
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Prichard's structures were not found in the atrial tissue from the bases of any of the 
conventional cardiac myxomas and the patients with these structures were, on average 10 
years older than the patients without them.  
Based on their results they stated that Prichard’s structure emerge as age-related senescence 
of endothelial cells with no apparent relation to histogenesis of CM.  
Val-Bern et all hypothesized that Prichard's structures emerge by infolding of terminally 
differentiated endothelial cells lining the endocardium as an irritational, excessive growth 
response to altered or turbulent blood flow, and in fact represent the cardiac version of the 
cutaneous senile angioma [132 and 133].  
 
Multipotential mesenchimal cells 
Immunohistochemical characterization of CM conducted so far resulted with heterogeneous 
phenotype, with neoplastic cells expressing various antigens (often within the same tumor) 
specific for different cell lineages including epithelial, endothelial, myogenic, myofibroblasts 
or neuroendocrine differentiation markers [1, 4, 12 and 110].  
Pluripotency of these primitive mesenchimal cells, heterogeneous phenotype of myxoma cells 
and different approaches in their morphological and immunohistochemical characterization 
are main reasons for somewhat conflicting hypotheses about the histogenesis of CM. 
 
Cardiomiogenic differentiation lineage 
To clarify the inconclusive data regarding the histogenesis of CM Kodama et all examined 
the expression pattern of several cardiogenic transcription factors (Nkx2.5/Csx, GATA-4, 
MEF2 and eHAND) specific to phenotype of primitive cardiomyocytes [134].  
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Expression of these transcription factors starts early in various regions of precardiac 
mesoderm and primitive heart tube but is later restricted to specific heart structure and 
maintained at higher levels in cardiac muscle cells of postnatal heart throughout the life.  
Using the immunohistochemical and RT-PCR approach Kodama et all confirmed their 
variable expression activity (slightly-to-intensely positive) in the nucleus and cytoplasm of 
tumor cells in all myxoma specimens (n=5). Furthermore, in situ hybridization for 
Nkx2.5/Csx was also positive for all myxoma while nested-PCR approach confirmed the 
expression of Nkx2.5/Csx in all and eHAND in 50% of cases.  
Contrary, myosin light chain kinase v2 (MLC-2v) specific for terminally differentiated 
cardiac muscle cells was RT-PCR negative.  
Based on those results Kodama et all concluded that expression of selected transcription 
factors specific to phenotype of primitive cardiomyocytes clearly suggests development of 
CM from multipotential mesenchimal progenitors with a cardiomiogenic lineage. 
Hypothesis that CM originate from remnants of primitive multipotential cardiogenic cells 
present in mature heart was further examined by Orlandi et all [135].  
Their findings suggest that neoplastic CM cells exhibit some phenotypic markers of 
embryonic endothelial-to-mesenchymal transformation (EMT) that precedes terminal 
differentiation of endocardial cushions and/or markers of primitive cardiac mesenchymal 
differentiation.  
Their concept is supported by morphological comparison of CM with embryonic endocardial 
cushions that has revealed substantial similarities between the endothelial lining cells, the 
cells within the cushion tissue and lepidic cells of CM [2]. 
Even the prevailing location of CM near the fossa ovalis on the left side of the interatrial 
septum could suggest their close relationship with fibrous cardiac structures and embryonic 
endocardial cushions from which they arise. 
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During the process of cardiac embryogenesis primordial endocardial endothelial cells 
involved in the EMT transformation (induced by signals from primitive myocardium) 
gradually change their expression pattern, lose apical/basolateral polarity and reduce the 
number of intercellular bonds.  
They break down the basement membrane (delamination), separate themselves from the 
endocardium, proliferate and gradually obtain migratory phenotype of mesenchimal cells. 
Concomitantly they invade the cardiac jelly (promotes the initiation of EMT transformation) 
and later participate in the formation of endocardial cushions. 
As a part of gradual alteration in their expression pattern, concomitantly with their EMT 
transformation embryonic endocardial endothelial cells progressively express mesenchimal 
markers (e.g. α-SMA), and shut of the expression of endothelial cell markers [133].  
Using the immunohistochemical and RT-PCR approach Orlandi et all confirmed the 
expression of α-SMA protein and/or transcript in majority (83.3%) of analyzed left-sided 
atrial myxoma (n = 30). They also detected focal expression of α-CA (α-cardiac actin) in only 
10% of specimens while expressions α-SKA (α-skeletal actin) was negative in all samples.  
Since expression of α-SMA is transiently expressed in cardiomyocytes during the early period 
of fetal development while α-CA and α-SKA are co-expressed in mature myocardium as 
prevailing isoforms, observed pattern of sarcomeric actin expression in lepidic cells of CM 
indicates their morphological similarity to primitive cardiac progenitors or primordial cardiac 
stem cells [136 and 137].  
Furthermore, α-CA is a major isoform of sarcomeric actin present in the cardiomyocytes of 
the 20 weeks old fetal heart (heart septation is completed and the heart poses all 
morphological characteristic of mature organ) with uniform expression throughout the 
myocardium.  
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Beside the heterogeneous and mutually exclusive expression of CD34 and α-SMA (primitive 
endothelial and myocytic markers, respectively) in different cells of atrial myxoma they 
detected a small number of neoplastic cells that co-express CD34 and α-SMA.  
The intermediate phenotype of CD34/α-SMA positive cells supports the concept of 
primordial differentiation of myxoma from early cardiac precursor cells. That is further 
supported by detection of focal co-expression of Flt-1and Flk-1 (early stem marker for 
endothelial cell precursors) [138].  
To further confirm their hypothesis Orlandi et all have performed RT-PCR analysis of several 
early cardiac differentiation markers and regulators (Notch1, WT1, NAFTc1, Sox9, ErbB3, 
SMAD6, MMP1, MMP2, CALB2, TIMP1). 
They detected the presence of CALB2, MMP2, TIMP-1 and Sox9 in all examined myxoma 
specimens (n = 8). Notch1 was observed in 87.5%, and NFATc1 in 37.5% of samples. 
Expression of ErbB3 and WT1 was absent in all specimens. 
Furthermore, more than 50% of samples were positive for MMP1 while SMAD6 was 
detected in only two cases.  
Their results support stated hypothesis and substantially correlates with the role of analyzed 
genes during EMT transformation of endocardial cells.  
However, based on those results Orlandi et all were not able to conclude whether the CM 
derives from embryonic remnants of cardiac cushions or primitive multipotential 
mesenchimal cells present in adult heart or even from ectopic de novo re-expression of early 
cardiomiogenic phenotype in adult cardiac cells.  
 
Neuroendocrine differentiation  
Detection of vasointestinal peptide (VIP) in some CM and their co-presentation with other 
features of CNC syndrome (lentiginosis, cutaneous neurofibromas, blue naevi, 
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phaeochromyocytomas and endocrine tumors in testis and pituitary gland) led Krikler et all to 
investigate their possible neuroendocrine origin [139].  
They immunohistologicaly examined expression of markers specific for neuroendocrine 
(protein gene product 9.5/PP9.5, neuron specific enolase/NSE, S100, synaptophysin 
p38/SYP), endothelial (von Willebrand factor VWF/FVIII, CD34) and smooth muscle cells 
(α-SMA) in 24 CM (3 were CNC) samples.  
Tumor cells (single stromal cells or cells in outermost layer of concentric vessel-like clusters) 
were positive for PP9.5 in 75% and S100 in 66.7% of cases while 50% of specimens were 
positive for NSE and 29.16% for SYP.  
Myxomas positive for NSE were also positive for S100 and PP9.5 while 58.33% of NSE 
positive tumors co-expressed SYP protein.  
Furthermore, surface of myxoma positive for PP9.5was partially covered with PP9.5+ cells.  
Only one CNC sample was positive (stromal cells) for PP9.5 and NSE.  
Cells positive for α-SMA were mainly found in the thick-walled blood vessels at the tumor 
base. Solid masses of proliferating smooth muscle cells unrelated to blood vessels were also 
found. 
Observed expression pattern of neuroendocrine markers and distribution of VWF/FVIII, 
CD34 (inner layer immediately surrounding lumens of vessel-like structures), and α-SMA led 
Krikler et all to suggest possible neuroendocrine origin of cardiac myxoma. 
Hypothesis of myxoma origin from multipotent mesenchimal cells capable of neural (and 
endothelial) differentiation was also suggested by Pucci et all [112].  
They immunohistochemically investigated 53 sporadic myxomas for neuroendocrine (PP9.5, 
S100, NSE) endothelial (FVIII/VWF, CD34, CD31, ulex europeus agglutinin/UEA-1), 
smooth muscle (α-SMA) and epithelial cell markers (carcinoembryonic antigen/CEA) as well 
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as cytokeratin CK 9p, atrial natriuretic peptide (ANP), VIP, calcitonin gene-related peptide 
(CGRP) and chromogranin (ChrA, ChrB). 
All neuroendocrine markers were detected in 57% of tumors while the most common co-
expression was found for PP9.5 and S100 (85%). Positive PP9.5 staining was detected in 
94%, S100 in 89% and NSE in 57% of cases. 
Immunoreactivity for α-SMA was noticed only in the media of blood vessels and in smooth 
muscle like cell groups interspersed in stroma (distinct from stromal cells).  
Expression of FVIII/VWF was observed in the inner endothelial layer of vascular-like 
aggregates, vessel endothelium and in stromal (23%) tumor cells. 
Another endothelial marker, CD31 was expressed by vessels endothelium of all cases (n = 6), 
while the stromal cells were also positive for CD34 (4/6) and UEA-1 (2/6) antigens.  
All stromal cells were negative for ChrA, ChrB, ANP, CGRP and VIP antibodies.  
Positive staining for CK 9p, CEA, S100, and NSE were also found in glandular epithelial 
structures (2 cases). Since their expression pattern overlaps with the pattern of endocrine cells 
from human gut epithelium, Pucci et all suggested that these glandular elements may 
represent rests of embryonic foregut. 
Furthermore, positive reaction for S100 and NSE was also observed in chondroid-appearing 
tumor areas. 
Neuroendocrine origin of CMs was further supported with findings of Teraccianno et all 
[140]. They detected strong and diffuse immunohistochemical staining of CALB2 
(calretinin/calbindin 2 protein normally detected in the cells of the central and peripheral 
neural tissue) in the cytoplasm and nucleus of neoplastic cells of all examined (n=24) 
sporadic CM cases [141].  
Furthermore, expression of CALB2 by ganglion cells in the fetal heart also supports 
endocardial sensory nerve origin of cardiac myxoma. 
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Hypothetical origin of CM from primitive mesenchimal cells is also supported by findings of 
Sakamoto et all [142].  
Using the enzyme-linked immunosorbent assay (ELISA) they detected increased (compared 
to human umbilical vein endothelial /HUVE/ cells) constitutive protein expression of 
Endothelin-1 (ET-1) and its precursor big ET-1 in cell lines established from CM tissue of 
two patients.  They also detected increased expression of IL6, IL8, CXCL1 and growth-
related oncogene α and no expression of stem cell factor, granulocyte colony-stimulating 
factor and hepatocyte growth factor in myxoma (and HUVE) cell lines. 
The obtained results prompt them to support the hypothesis that CM originates from 
mesenchymal cells capable of endothelial differentiation. 
CXCL1 chemokine also serves as autocrine factor for melanoma cells and as neutrophil 
chemoacttractant and angiogenic factor as well. Overexpresion of growth related oncogene α 
promotes tumor growth and metastasis and its presence in cardiac myxoma, together with 
CXCL1, may further explain the reported malignant potential of some CM.  
Recently, after histological and electron microscopy examination of 168 cases, Rogov et all 
had revealed signs of embryonal endothelium capable of vasoformation and 
glycoprotein/glycosaminoglycan synthesis in neoplastic cells of CM [143].  
According to them CM is a true benign dysontogenetic tumor originating from embryonal 
endothelium but the term myxoma does not faithfully reflect its true morphological entity so 
they suggested the name embryonal endocardial endothelioma [143].  
Johansson and Curschellas et all suggest myxoma origin from embryonic cell remnants 
(based on expression of F8, Des, VIM, cytoceratines, S100, LU5, CAM5.2 and NSE) while 
Farrell et all and Lindner et all (based on observed expression of CD34, CD31, CEA and 
CA19.9) suggested their endodermal origin [144, 145, 146 and 147].  
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Bioinformatic analysis 
Bioinformatic analysis [performed with the aid of the online DAVID database- The Database 
for Annotation, Visualization and Integrated Discovery software v6.7, 
http://david.abcc.ncifcrf.gov/] of currently known markers and antigens (whose data are 
publicly available in corresponding literature databases) expressed by CM (see Table 1.) and 
grouped by functional annotation clustering (default parameters) reveals 34 key protein 
markers possibly related to histogenesis of CM and development of their heterogeneous 
cellular and structural components.  
Due to the unspecific nature of investigated cell lineage markers this approach only confirms 
their overlapping functionality in various developmental processes such as: endothelial-to-
mesenchimal transformation (NOTCH1, SOX9, NAFTC1), mesenchymal cell differentiation 
(NOTCH1, SOX9, EDN1, EDN3, NAFTC1), cell fate commitment (NOTCH1, SOX9, FGF2, 
KDR), regulation of cell development (NKX2.5, NOTCH1, TIMP2, EDN1, FGF2, MIB1, 
SPP1), heart development (GATA4, NKX2.5, NOTCH1, SOX9, ENG, EDN1, HAND1, 
MIB1, MYH10, NFATC1, ACTC1, PKP2), heart looping (GATA4, NKX2.5, ENG, HAND1, 
MIB1), muscle cell/tissue differentiation and development (ACTC1, NKX2.5, KRT19, RB1, 
ENG, HAND1, MYH10, PDGFRB, TNC) regulation of muscle development 
(GATA4,NKX2.5, NOTCH1, FGF1), neuron differentiation (CD44, NOTCH1, EDN3, 
FGFR1, IL6, MYH10, UCHL1/NSE, VEGFA), regulation of neuron differentiation (NKX2.5, 
NOTCH1, TIMP2, MIB1, SPP1), epithelium development (CD44, ENG, KDR, MIB1, 
VGFA), ectoderm and epidermis development (NOTCH1, SOX9, KRT9, PDGFA), skeletal 
system development (SOX9, EDN1, FGFR1, MMP14, MMP2, MMP9, PDGFRA, PDGFRB, 
SPP1), ossification (MMP14, MMP2, SPP1), bone development (SOX9,MMP14, MMP2, 
SPP1) and angiogenesis (NOTCH1, ENG, EDN1, FGF2, FLT1, HAND1, IL8, KDR, 
MMP14, PDGFA, TYMP, VEGFA). 
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Key proteins expressed in CM are also involved in various overlapping signaling pathways 
(e.g. G protein coupled receptor signaling pathway, VEGFR signaling pathway, TGFß 
receptor signaling pathway, MAPK signaling pathway, cytokine-cytokine receptor interaction 
and intracellular signaling cascade), cell cycle regulation and cell proliferation, apoptosis, cell 
adhesion and cell migration and metastasis (Table 1.). 
Gene functional classification of protein markers performed by the same program (DAVID 
database) reveals only three functionally related groups of gene/protein markers mainly 
related to: metalloproteinase involved in extracellular matrix remodeling (MMP1, MMP2, 
MMP3, MMP9, MMP14), cytoskeletal intermediary filaments (KRT7, KRT8, KRT9, 
KRT19, KRT20, DES, VIM) and tyrosine specific protein kinase related activities (FLT4, 
PDGFRB, FGFR1, FLT1, KDR). 
Presented results of functional annotation gene clustering are in good agreement with the 
extensive bioinformatics study reported by Barh and Parida in 2009, which have found key 
CM protein markers to be involved in G protein signaling, heart development, angiogenesis, 
cell proliferation, cell adhesion, cell migration and metastasis [12]. 
After extensive literature search they grouped all molecular markers found in CM based on 
their expression pattern (expressed, down regulated up regulated and highly up regulated in 
malignant cases) and used them to construct protein-protein interaction maps [Osprey 1.0.1 
software powered with human GRID database 
(http://biodata.mshr.on.ca/osprey/servlet/Index)], general disease pathway (using the data 
from Invitrogen, KEGG, BioCarta, Ambion, and Cell Signaling pathway database) and finally 
for the construction of final critical disease pathway responsible for cardiac myxoma 
development (obtained by the Cell Designer 4.0 beta software used for analysis of signaling 
networks, key nodes and up and down-stream target analysis). 
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Their results shows that common myxoma molecular markers interact with various other 
proteins involved in numerous biological processes such as tumorigenesis, heart development, 
and NOTCH and growth receptor signaling pathways.  
Several disease pathways were found to interplay with each other with the main pathways 
including CCR2, FMOD-TGFB, S100A1-FGFR, NKX2.5-GATA4-SOX9-FGFR, HAND1-
GATA4, and MUC1.  
For example, some proteins involved in heart development (GATA4, SOX9, HIND1) interact 
with the signaling receptors by growth factors via KPNB. The NOTCH1 and several 
mitogenic pathways associated with them over the MUC1 whereas F8, THBD, FMOD, 
PLA2G2A, CCL2 and CCR2 interact with the rest of protein network via MMP2 protein. 
At the certain point majority of these pathways were found to follow the growth receptor 
signaling pathway with CCR2, TGF-β, MUC1, FGFR, EGFR, GATA4 and HAND1 
identified as their key node elements and MYC, FOS and MMP9 as one of the common 
downstream targets. 
All these key nodes, their regulators and upstream and downstream targets can be considered 
as potential drug targets that can be used to block the specific pathways responsible for CM 
development. 
 
Microarray analysis 
Performed bioinformatics analyses are expectedly biased by the short extent and type of 
antigens and protein markers investigated so far to phenotype CM, with most of them used 
just to decipher the specific (endothelial, cardiomyogenic or neuroendocrine) cell source of 
myxoma origin. 
More reliable and extensive data for investigation of regulatory pathways activated in tumor 
cells, identification of the myxoma cell origin and better understanding of their various 
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clinical manifestations and reported malignant/metastatic potentials can be obtained through 
global gene expression analysis using either cDNA or other recently developed mRNA or 
protein and miRNA microarray platforms combined with laser capture technology 
(homogeneous sell source) and conformation of obtained data through qPCR or various 
immunohistological and blotting techniques.  
So far only one global microarray study has been reported by Skamrov et all [97].  
They performed the cDNA expression array analysis of seven sporadic CM cases comparing 
them with the expression profile of a selected group of physiologically normal tissues (blood, 
aorta, heart, brain, lung, spleen, kidney, liver, small intestine, skeletal muscle, pancreas, 
stomach, colon, bone marrow, and skin).  
After extensive bioinformatics analysis (taking into account only the genes that have the same 
order of expression intensity in no more than two out of 15 used normal tissue controls) they 
ended up with the narrower sets of genes (out of 5200 analyzed) that can be potentially used 
as molecular markers of CM. The data were further confirmed by the gene specific RT-PCR 
analysis. 
Obtained results clearly showed that CM could be viewed as standalone histological entity 
rather than a pathological modification of normal neighboring tissue. 
Interestingly, according to applied criteria, antigenic markers commonly discussed in 
connection with CM (S100, CCL2/MCP1, CD34, FVIII/vWF and FVIII related protein, 
vimentin and laminin) were not selected as specific markers since they exhibit either high 
level of expression in number of used control tissues or high variability in examined CM 
samples. 
Gene markers specific for endothelial, smooth muscle and blood cells did not showed 
dramatic variability suggesting that those cellular elements were present in more or less 
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constant proportions in examined CM cases while markers for normal cardiomyocytes 
showed relatively low and highly variable expression level.  
The most prominent expression among selected mRNA markers steadily expressed in CM, 
was shown by MIA and PLA2G2A (more than 10 fold higher expressions compared to 
controls) and together with PLTP they also showed the highest specificity. 
Interestingly both of them have proven role in progression of various malignant diseases. 
Contrary to the role of MIA in melanoma development, increased expression of PLA2G2A in 
human adenocarcinomas of the stomach substantially correlates with higher life expectancy 
and lower risk of metastasis. 
Selected CM markers are involved in phospholipids metabolism (PLA2G2A, ANXA3, 
PLTP), regulation of cellular proliferation and inhibition of proteases involved in ECM 
remodeling (TIMP1, SLP1) while others function as modulators of ECM-cell interactions 
(MIA, SPP1, FMOD), transcription factors (SOX9) or intracellular calcium binding proteins 
(CALB2). 
The presence of genes, specific for chondrocytes development (SOX9, MIA, SPP1) within the 
selected group of CM markers also indirectly supports their origin from primitive 
multipotential mesenchymal cells.  
 
Cytogenetics  
CM exhibits distinct aneuploid/tetraploid DNA pattern and karyotype heterogeneity even 
within the different areas of the same tumor [1, 2, 3 and 8].  
Most of the reported cytogenetic data relate to patients with familial pattern of the disease 
(CNC) that exhibits various chromosomal abnormalities primarily involving chromosome 2, 
12 and 17 [19, 20, 21, 148, 149. 150. 151, 152, 153 and 154]. 
31 
 
Initial linkage gene analysis indicated the existence of two major CNC loci possibly harboring 
the myxoma susceptibility genes: CNC1 located at 17q22-24 and CNC2 located within the 
chromosome 2p16  
The CNC1 susceptibility gene recently identified by two independent research groups is the 
PPKAR1A gene that encodes the R1α regulatory subunit of cAMP dependent protein kinase 
A (PKA) involved in G protein receptor signaling pathways [20, 21and 151 ]. 
Mutations in PRKAR1A were found in up to 80% of patients with familial history of CNC 
with only a few reports among sporadic myxoma cases [1, 20 and 21]. 
More recent large, transatlantic consortium study of 353 patients who carried a germline 
PRKAR1A mutation or were diagnosed with CNC and/or PPNAD disease revealed the 
existence 80 different PRKAR1A gene mutations. Among them 6 were missense mutations; 
19 were nonsense mutation; 20 mutations involved splice-site; 33 caused a shift in reading 
frame (through insertion, deletion or another change involving a few base pairs) and two were 
characterized as deletions involving large intronic and exonic areas of the gene [155].  
They were randomly distributed throughout the coding area, although mutations involving 
exons 2, 3, 5, 7 and 8 were more frequent. There were also two observed single mutational 
hot spots [c.491-492delTG in exon 5 and c.709-7del6 in intron 7] that occurred independently 
in several unrelated families of various ethnic backgrounds. 
Certain mutations were more frequent and provided some genotype-phenotype correlation. 
There were also observed gender differences among carriers of PRKAR1A mutations with 
PPNAD disease occurring earlier and more frequently in female patients, suggesting the 
existence of some tissue specific microenvironmental factors that may modify their 
tumorigenic potential. 
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Most PRKAR1A mutations (63) resulted with shortened, premature transcripts subjected to 
selective degradation through nonsense-mediated mRNA decay (NMD) that leads to R1α 
haploinsufficiency and increased activity of PKA enzyme [21, 151, 156 and 157].  
Only small subset of PRKAR1A mutations discovered so far are not subject to NMD 
mechanism, but they also result with dysfunctional protein and haploinsufficient CNC 
phenotype with increased PKA activity and more aggressive disease outcome [17 and 19].  
Depending on the type of affected tissue downstream signaling effects of altered PKA action 
may include changes in metabolism, ion transport, hormone production and gene transcription 
with consequent alterations of cell cycle and induction of tumorigenesis but its exact role in 
tumorigenesis of cardiac myxoma has still to be established.  
Rare individuals with a missense mutation (e.g. R74C), whose mRNA escapes NMD and is 
expressed as mature mutant protein seems to have the same haploinsufficient R1α phenotype 
suggesting the possible existence of yet another molecular mechanisms not limited to 
inadequate control of PKA catalytic subunit but with different protein interactions (e.g. with 
PAP7 protein) responsible for increased tumorigenic potential of familial myxoma cases.  
Recent genetic studies of a large family with CNC syndrome co-segregated with autosomal 
dominant TPS disorder [trismus-pseudocampodactility syndrome (TPS), also referred as 
Hecht-Beal syndrome] led to discovery of novel CNC gene locus mapped to chromosome 
17p12-31. [155]. 
Sequence analysis performed at this locus showed a missense mutation (Arg674Gln) in the 
perinatal isoform of the myosin heavy chain gene MYH8.  
Mechanism through which the mutation of MYH8 causes development of CM is still 
unknown. But since perinatal myosin is expressed in myofibroblasts it is speculated that 
MYH8 may act as a developmental switch that governs the loss of multipotent nature of 
primitive cardiomyogenic cells and their differentiation into a non-proliferative mature 
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myocardial tissue. It was hypothesized that mutations of perinatal myosin gene might promote 
the survival of multipotent progenitor cells in mature heart and provides a substrate for 
second tumorigenic genetic event (e.g. PRKAR1A mutation) that result in CM development. 
That hypothesis is in agreement with Knudson two-hit model of tumorigenesis but also with 
hypothetical origin of CM from residual sub-endocardial primitive stem cells. 
Somatic alterations (amplifications, deletions) of CNC2 were observed in a large number of 
CNC patients but susceptibility gene has not been detected, and families initially assumed to 
have a major mutation in that region were subsequently linked to chromosome 17q24 [158]. 
The frequency of amplifications on 2p16 locus among CNC patients, including those with 
germline, inactivating PRKAR1A mutation suggests the presence of an oncogene whose 
increased activity may serve as another molecular event responsible for tumorigenesis in at 
least a subset of families with a CNC syndrome [21 and 153]. 
Previously mentioned consortium study has also revealed for the first time some phenotypic 
differences between patients with CNC1 defects ant those with aberration in CCN2 locus but 
without PRKAR1A mutation. The later seemed to present later in life, were unlikely to have 
familial history of the disease and were less likely to develop myxomas, thyroid tumors, PMS 
and LCCSCT. 
In contrast to genetic abnormalities in CNC patients no single gene mutations responsible for 
sporadic myxoma has been discovered. 
Furthermore, cytogenetic analyses performed on sporadic CM have shown no role for 2p16 
chromosome and only a limited involvement of structural rearrangements within 17q2 
chromosomal region leading to conclusion that they are not genetically related to familial 
cases and that some other yet unknown mechanism must be responsible for their histogenesis 
[159] 
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However, detected clonal and more frequent non clonal structural aberrations such as 
microsatellite instability (e.g. ANK1, D2S105, D3S647, D7S479, D7S520, D17S250, 
D17S579, D17S855, D19S49), telomeric associations [e.g. tas(13;15)(p11.2;p11.2)], deletions 
(loss of the Y chromosome), translocations  [e.g. translocation between  chromosome 1 and 
12 with a breakpoint at 12p12, addition (1)(q32) from unknown region etc.] and other 
rearrangements found in  various sporadic CM cases particularly in chromosomal regions 
12p1 and 17p1 suggest that these chromosomal rearrangements may contribute to tumorigenic 
pathways and progression of sporadic myxoma [17, 20, 160, 16, 162, 163 and 164].  
However, whether there are any susceptible genes in these or neighboring regions that are 
related to the observed genetic instability has still to be elucidated. 
 
Epigenetics of cardiac myxoma- a road yet to be taken 
Reviewing the literature, and with the help of cardiovascular databases 
(www.cardio.bjmu.edu.cn) Barh and Parida have also identify set of genes common to the 
processes of heart development and histogenesis of cardiac myxoma: NKX2.5/CSX, GATA4, 
HOX, HAND, MYOD, SOX4-6, S100 and TGFβ.  
However, these genes are active at the early stage of embryonic heart development (mainly 
during EMT process) while majority of CM develops much later in middle age patients with 
very few cases registered in the early postnatal period of life[12 and 165]. 
That prompted Barh and Parida to speculate a possible role of epigenetic factors in 
reactivation and ectopic expression of these early embryonic heart genes that may contribute 
to CM development in much later, adult stages of life. 
Epigenetic mechanisms are defined as inherited and/or acquired, mitotically and meiotically 
stable and reversible changes in phenotype that occur without the alterations in nucleotide 
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sequence of affected genes but control their temporal, spatial and quantitative expression 
patterns.  
The important epigenetic mechanisms include DNA methylation of cytosine residues in CpG 
islands of gene regulatory elements, post-translational covalent modification of histone 
proteins or their replacement with alternative isoforms and/or non-coding RNAs (e.g. micro-
miRNA) that are not translated into proteins but play essential roles in the post-transcriptional 
control of gene expression through complementary binding to their specific mRNA targets.  
A sophisticated interplay between these epigenetic events changes chromatin conformation 
and patterns of gene expression (modulation, activation or inactivation) and is important in 
various developmental and disease processes. 
For example, various miRNA molecules have already been associated with pathologic 
alteration of gene expression during progressive development of cardiovascular diseases such 
as hypertrophy of the heart. Furthermore recent in vitro experiments also showed that the 
methilatyon of genes and/or posttranslational epigenetic changes of their proteins (e.g. 
HDAC1, GATA4, H3 and H4) also play an important role during cardiomyogenic 
differentiation of multipotential mesenchymal stem cells in murine models [167, 168, 169 and 
170].  
Using a bioinformatics approach Barh and Parida selected a group of miRNA molecules (let-
7, miR-125, miR-205, miR-214, miR-217 and miR-296) that may target majority of 
previously mentioned key molecular markers and potentially influence the entire critical 
disease pathway/s responsible for myxoma histogenesis [12]. 
However, until now there is no reported data neither for miRNA gene expression nor for other 
epigenetic factors possibly involved in histogenesis of CM and the precise role of these 
epigenetic modulators and putative therapeutic molecules has still to be experimentally 
elucidated. 
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Conclusion and further directions 
Despite so many immunohistological and other studies the cellular origin of CMs is still 
controversial. The phenotypic expressions of tumors that originate from multipotential 
mesenchimal cells is often variable and maybe misleading, revealing just one feature of tumor 
tissue, which does not necessarily reflect the true origin of their cells or the main signaling 
and regulatory pathways responsible for their molecular pathogenesis.  
Furthermore, all markers studied in CM tissue are not exclusively specific for endothelial, 
cardiogenic or neuroendocrine differentiation lineage and could be variably expressed in 
number of other cell types or ectopically re-expressed in adult tissue due to some kind of 
epigenetic deregulation. 
Due to the rarity of the cardiac myxoma (small number of cases in one institution) and lack of 
comprehensive experimental data particularly concerning the recurrent cases, myxoma with 
metastatic dissemination and secondary lesions with malignant nature, more extensive multi-
institutional approach involving the application of recently developed technology is crucial 
for better understanding of their biological background, molecular pathogenesis and for 
elucidation of their cell(s) of origin.  
Advent of omics-technology with its unprecedented potential for concomitant investigation of 
complete cell transcriptome (on mRNA and miRNA level) in normal and pathological 
conditions, bioinformatic analysis of obtained data and their comparisons with the data from 
epigenetic and proteomic approaches enables a comprehensive investigation of entire CMs 
signaling networks and regulatory pathways and elucidation of their key molecular markers 
and their potential as drug targets.  
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